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Conclusions Acknowledging that very few centers in the 
world, if any, likely fulfill the requirements here presented, 
the document may be a tool to guide improvements of care 
delivery to patients with pituitary disorders. All these crite-
ria must be accommodated to the regulations and organiza-
tion of Health of a given country.
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Introduction
The pursuit of excellence is a continuous endeavour for 
health professionals and is increasingly sought by society 
and health administrators alike. It is widely accepted that 
only experts in a field may provide the best standard of care 
to patients. In this context, pituitary tumors are more fre-
quent than previously thought [1, 2] and present a significant 
challenge for diagnosis and management. There is a widely 
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held consensus endorsed by publications in the field, indi-
cating that the best care for these patients is provided by 
an interdisciplinary team composed of dedicated endocri-
nologists and experienced pituitary surgeons working in 
collaboration [3, 4]. Such a core team needs to be supported 
by a collaborative environment of specialists in other areas, 
such as neuroradiology, neuropathology, radiation oncology, 
neuro-ophthalmology, otorhinolaryngology, plus trained 
nursing [4].
The goals of that team should include: (1) early detec-
tion of the tumor; (2) establishing the diagnosis; (3) deter-
mination of the most suitable treatment, which can either 
be observation; surgical, medical or radiotherapy; (4) if 
surgical, removing the pituitary mass while preserving the 
normal pituitary tissue and nearby structures; (5) the surgi-
cal or medical treatments working alone or concomitantly 
must eliminate hormonal hypersecretion and/or its effects; 
(6) prevention of tumor recurrence; and (7) recognizing 
and caring for the acute and delayed complications of the 
disease, especially hypopituitarism. The final goal is the 
elimination or at least reduction of the excess morbidity 
and mortality associated with the tumor and hyperse-
cretion syndrome as well as treatment of accompanying 
pituitary hormone insufficiencies [3–5]. For many patients, 
this requires a program of care, including medical therapy, 
surgery and radiation therapy, in addition with long-term 
follow-up.
The need for Pituitary Tumor Centers 
of Excellence (PTCOE)
The concept of a Center of Excellence has been promul-
gated in various fields of medicine to address public and 
professional concerns regarding the quality of care of a 
given group of patients. This concept has been found to 
be useful primarily in activities involving multidiscipli-
nary teams and more often in teams that are composed 
of experts in surgical techniques and medical treatments 
[6–8]. In some centers treating pituitary tumors, high-
level interdisciplinary groups are already developed and 
effectively function, but in most cases, these groups are 
self-appointed structures without formal acceptance by 
hospital managers, or health authorities, no by their col-
leagues, and there are no formal definitions of the criteria 
needed to be considered truly “excellent” [4]. If there are 
no explicit requirements for achieving a degree of excel-
lence, patients’ outcomes cannot be accurately measured, 
and the fulfillment of the previously outlined goals cannot 
be determined. In addition, the evaluation and accredita-
tion of such structures by external and independent bodies 
are not performed.
Despite efforts to foster improved adherence to the rec-
ommended standards being available, a major barrier to opti-
mal care in patients with pituitary tumors is a delivery sys-
tem that too often is fragmented, lacks clinical information 
capabilities, duplicates services, and is not well designed for 
the delivery of co-ordinated chronic care.
The relationship between quality and outcome has 
been intuitively affirmed by endocrinologists who have 
a “preferred pituitary neurosurgeon” to whom they refer 
patients. However, in a given hospital, efforts by endocri-
nologists or administrators for example to limit surgical 
procedures to a single surgeon, may encounter firm oppo-
sition by the neurosurgery staff stating that “a graduate 
in Neurosurgery can perform any intervention”. In such 
situations, surgeons perform all of the activities without 
sub specialization. In the absence of external guidelines 
generated and endorsed by authoritative bodies, the status 
quo is unlikely to change.
A relevant point when dealing with the concept of a 
PTCOE is performance of scholarly scientific discovery 
and the transparent communication of results and out-
comes. Units formed by a lone endocrinologist or an indi-
vidual neurosurgeon will have difficulty communicating 
results to symposia and administrative organizations. This 
is a crucial point in eliminating “communication bias”, i.e., 
the fact that small groups or groups that perform poorly 
never present results. Therefore, the literature is full of 
reports from the more successful groups in the world 
with the best outcomes and this bias contributes to the 
fact that there is limited understanding of the true results 
when evaluating outcomes of new drugs or new surgical 
approaches. In this context, the implementation and use 
of disease-specific registries and electronic clinical files 
may provide a reliable tool with which to communicate 
unbiased results. As part of their mission, endocrinologists, 
as well as neurosurgeons and other specialists caring for 
patients with pituitary disorders, have a duty to make pro-
gress in the pituitary sciences, and this is only attainable 
through teamwork.
Articles indicating the need for Centers of Excellence for 
pituitary diseases have mostly focused on surgical proce-
dures outcomes [9–15]. Despite convincing arguments, such 
efforts have not yet been able to change the general surgical 
practice. On occasion, health or administrative authorities 
have attempted to define the characteristics of such centers 
of excellence, but frequently, the main goal was to reduce 
costs, and these characteristics have not been accepted by 
the professionals involved in the day-to-day care of the 
patients. For such reasons, a practical and effective defini-
tion of a Pituitary Tumor Center of Excellence (PTCOE) 
is needed, and the characteristics of such are summarized 
herein.
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BOX 1. General characteristics of a PTCOE are:
Provide the best care for patients with pituitary tumors and related 
pathologies
Independent of health authorities, administrations and for-profit 
organizations
Widely recognized by endocrinologists and pituitary surgeons
Aimed to the advancement of pituitary science
Providing adequate patient education and community outreach
Recognized by external national and/or international endocrine and 
neurosurgical medical societies
Act as training center for residents in the treatment of pituitary 
pathologies
Based on the characteristics outlined above, we conclude 
that to provide the best care to patients with pituitary tumors, 
it is desirable to identify PTCOEs in a given health system 
area. For a group of endocrinologists who specialize in pitui-
tary disorders and pituitary surgeons participating in such 
units, it is mandatory to know in an explicit way the require-
ments and conditions needed to develop such a center and 
to evaluate its success. These need to be established by an 
external learned body that may or may not perform the final 
step of validation of the center.
BOX 2. Mission of the PTCOE
1. Provide the best standard of care to patients with pituitary tumors 
and disorders
2. Organize multidisciplinary clinical management
3. Liaision between experienced neurosurgeons and expert neuroen-
docrinologists
4. Work with the supporting specialties
5. Train fellows in the management of pituitary tumors and related 
disorders
6. Provide courses, publications and lectures for primary care physi-
cians and other specialists
7. Capture and track clinical data
8. Provide up to date and comprehensive patient information
9. Present results and outcomes to scientific bodies and administra-
tors
10. Support endocrine units located outside the PTCOE
11. Advise health administrators and authorities on specific prob-
lems
12. Advance the science and scholarship of pituitary tumors
13. Include tumor data on National or Regional registries
A PTCOE need to envisioned on a “patient centric” 
organization, as the patient is the core of its mission Patient 
Networks, engagement activity, family impact, educational 
platforms, digital infrastructure to facilitate care across 
primary-secondary health care, and across specialties are 
essential for a properly focused PTCOE.
Excellence in pituitary surgery
Although advances in the medical treatment of pituitary 
tumors over the last decades have been stellar, it is beyond 
doubt that a PTCOE is dependent on the presence of a 
dedicated and excellent group devoted to pituitary surgery 
by the endonasal transsphenoidal or transcranial approaches.
In fact, assuming that modern techniques of imaging, and 
neuronavigation are available at a given center, the pres-
ence of an experienced neurosurgeon capable of perform-
ing pituitary microsurgery in a safe and effective manner is 
mandatory. Pituitary surgery is the most effective procedure 
for acromegaly, Cushing’s disease, TSH-secreting adeno-
mas, resistant prolactinomas and non-functioning pituitary 
adenomas causing mass effects. It is also effective for pitu-
itary apoplexy, diagnostic uncertainly as to the nature of 
the lesion and, in the rare cases of pituitary cancer. This 
approach is also recommended for para-sellar pathologies, 
such as craniopharyngiomas, Rathke cleft cysts, some chor-
domas and some skull base meningiomas [9].
BOX 3. Targets of pituitary surgery
1. Eliminate pituitary hypersecretory syndromes
2. Eliminate, reduce or control the tumor mass
3. Preserve the normal pituitary gland function
4. Preserve surrounding neural structures, including the optic 
apparatus, other
cranial nerves and parasellar vasculature
5. Reduce or eliminate acute complications generated by the tumor
6. Reduce or eliminate the risk of tumor recurrence
Although defining targets for pituitary surgery is rela-
tively easy, defining excellence for an individual pituitary 
surgeon is considerably more difficult. An excellent neuro-
surgeon requires a solid knowledge of hypothalamic-pitu-
itary organ physiology and the principles of its endocrine 
evaluation, plus continuous practice to maintain his/her level 
of surgical expertise; otherwise, the quality of the surgeon’s 
work may deteriorate.Therefore, an experienced high-level 
pituitary neurosurgeon requires solid training in basic neu-
rosurgery and continuous practice, and the latter is based 
on a continuous high workload and demonstrated evidence 
based outcomes.
The basic knowledge of neurosurgery relies on a resi-
dency program that is a sine qua non for a future excellent 
neurosurgeon. However, in most centers in most countries, 
the program provides limited experience in transsphenoidal 
pituitary surgery. This is because most residency training 
centers perform a small number of transsphenoidal surger-
ies per year. This situation does not allow the graduate to 
gather enough experience to be able to practice indepen-
dently immediately after completing training [9].
Conversely, specific intervention to the pituitary region 
through an endonasal approach requires a clear understanding 
of skull base anatomy and the expertise necessary to maneu-
ver instruments and the endoscope in such a narrow surgical 
space [16, 17]. In addition, the residency training program for 
a neurosurgeon is so demanding that graduates have insuf-
ficient experience in management of pituitary patients, and 
492 Pituitary (2017) 20:489–498
1 3
insufficient interactions with neuroendocrinologists. For these 
reasons, a graduate who wishes to have a significant pituitary 
tumor practice in the future should have an additional fellow-
ship at a high-quality center performing a large number of 
interventions each year [18]. With such a combination of a 
residency plus a fellowship, the future pituitary tumor surgeon 
should then have the appropriate education and training.
After the residence, depending on the training opportu-
nities available at a given country, we would recommend 
either (1) completion of a formal postgraduate fellowship 
in pituitary surgery, (2) completion of a postgraduate fel-
lowship in skull base or neuro-oncologic surgery at a high 
volume pituitary center, or (3) completion of postgraduate 
subspecialty training at a high volume pituitary center.
BOX 4. Basic requirements for excellence for a given neurosurgeon 
using transsphenoidal procedures
1. Basic residency training in neurosurgery at an accredited center
2. Post-residency fellowship (12–15 months) in an active, high-level 
pituitary surgery unit, or extensive training in pituitary surgery 
and pituitary patient management at an established pituitary 
center
3. Continuous practice in a newly created or previously recognized 
unit with a high pituitary workload and demonstrated outcomes
4. Contribute to the advancement of Pituitary Science through pub-
lications in medical journals, chapters in books and monographics
Pituitary surgery. Outcomes and expertise
One of the peculiarities of surgery in general, and of pitui-
tary surgery in particular, is that if a superbly trained sur-
geon does not maintain a high number of operative cases 
in the following years, the surgeon may lose the capability 
of performing at an excellent level. Expertise then requires 
basic training, specific training and continuous practice. For 
such reasons, several reports have shown that experienced 
surgeons have better outcomes and lower rates of compli-
cations than surgeons with less experience [9, 19–24]. In 
a US national survey on complications of transsphenoidal 
surgery conducted on a large number of active neurosur-
geons, respondents were divided into three groups depend-
ing on number of pituitary surgeries performed along their 
life-long experience. The morbidity and mortality was lower 
for the surgeons with more interventions, and the rate of 
complications was lower. Despite that, the most experienced 
surgeons witnessed more severe complications in absolute 
terms, related to the high numbers of operative procedures, 
and also because they operate on the most complicated cases 
[24]. Additionally, in cases of surgical reoperation when the 
first surgery is complicated or fails, surgical experience is 
crucial for obtaining optimal results [25–28].
After having a neurosurgeon with the correct training 
during residency who afterwards performs a fellowship at a 
high level center, what makes the difference between expe-
rienced and less experienced surgeons? The answer is the 
number of procedures performed by the surgeon per year. In 
fact, reports from UK centers that have expertise in pituitary 
tumors have observed that surgeons with a high workload 
have better outcomes. For a hospital treating a fixed popula-
tion, a smaller number of surgeons produce better outcomes, 
and centers with only one neurosurgeon performing pituitary 
surgery have better outcomes than centers with several such 
surgeons [19, 20, 22, 29–31].
These observations have been endorsed by groups in other 
countries. A high workload, i.e., a high number of procedures 
performed each year, provides the neurosurgeon using the 
transsphenoidal approach with sufficient experience with 
respect to patient selection, operative techniques, and better 
outcomes, in addition to reducing the rate and severity of 
complications [9, 15, 21, 22, 24, 32, 33]. Finally, evaluation 
of efficacy must be based on outcome data [34, 35].
Box 5. Experienced pituitary neurosurgeon for PTCOE: rationale and 
definition
1. Experienced pituitary neurosurgeons have better outcomes, and 
reduced rates of morbidity and mortality
2. The workload of a surgeon is based on the ratio between the 
number of operating surgeons and the size of the population 
served by the center
3. For a fixed number of inhabitants covered by the center, a 
reduced number of transsphenoidal pituitary surgeons results in 
better outcomes
4. The ideal number of transsphenoidal pituitary interventions for 
micro and macroadenomas for
an individual surgeon is debatable but should be approximately 50 
per year
Assuming that expertise or excellence comes from the 
workload of a well-trained surgeon, and considering that 
most centers serve a fixed number of inhabitants, the solu-
tion proposed by several publications would be to have a 
limited number of surgeons devoted to pituitary tumors at 
each center, with a backup for emergency cases.
A single neurosurgeon situation, however, has several 
drawbacks. For example, the center will remain uncovered 
when the surgeon is absent, the training of new fellows would 
be difficult, and performing clinical research and commu-
nicating results could be impeded. For such reasons, one 
alternative could be to concentrate several neurosurgeons 
(two to four) at a given center that covers the transsphenoi-
dal surgery needs of a whole region that ideally has 2.5 to 
5 million inhabitants. Such a center would receive patients 
who were generated locally but also referred from endocrine 
units located at other hospitals in the region, i.e. “regionali-
zation” for a pituitary center [11]. The regionalized center 
can receive patients already diagnosed, perform the inter-
vention, and return the patient for follow up at the hospi-
tal or physician of origin. This process may be facilitated 
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by implementation of electronic clinical registries working 
within a network. As the number of patients with pituitary 
diseases is not large, such an organization should be satisfac-
tory in cost-benefit terms for health administrators, even con-
sidering the travel costs of the patient to the reference center.
Box 6. Organization of a neurosurgical center for a PTCOE
1. Expertise is based on workload, i.e., the quotient between a lim-
ited number of surgeons and a high number of patients
2. An alternative to reducing the number of surgeons performing 
transsphenoidal pituitary procedures is to expand the population 
covered
3. Having more than one neurosurgeon is convenient in terms of 
continuing access, training new fellows and scientific progress
4. An ideal reference center for a region may be formed by 2–4 
expert neurosurgeons performing transsphenoidal operations, 
including macro and micro adenomas serving a population of 2.5 
to 5 million inhabitants, with a proportional increase in the work 
load
5. Such a regionalized unit can give surgical coverage to several 
external endocrine centers of excellence, and can return the 
patient to his/her local hospital for follow-up after surgery, accord-
ing to follow up protocols
Endocrine Units of Pituitary Tumors Centers 
of Excellence
A PTCOE requires that the neurosurgery group works closely 
with an endocrinologist on an endocrine unit or a division 
that has a special emphasis on pituitary diseases. Obviously, 
pituitary diseases are not only tumors but encompass other 
pituitary pathologies and include the secondary effect of 
tumor treatment, such as central hyposecretion of TSH or 
LH/FSH, GH deficits, panhypopituitarism, as well as, Shee-
han syndrome, diabetes insipidus, and so on, which are all 
managed by the same professionals [34–38]. At the end the 
endocrinologists need to serve a “generalist role” for a life 
long term and provide an holistic management for the patient. 
Only a combination of expert neurosurgeons working in liai-
son with expert neuroendocrinologists can provide the excel-
lence of care needed to meet the definition of a PTCOE. This 
team will use advanced techniques of diagnoses and treat-
ment, produce scientific reports, and present their results to 
scientific bodies and administrative authorities.
The mission of the endocrine component of the PTCOE 
includes suspecting pituitary disease, establishing the diag-
nosis, determining the optional treatment plan with neuro-
surgeons regarding surgical intervention, providing support 
for peri-operative care, and providing long term follow up 
management. Also document and manage any endocrine 
deficiencies across radiation procedures.
Defining expertise for an endocrinologist appears to be 
easier than for a neurosurgeon considering that the requir-
ing workloadhas not be determined. It is evident, however, 
that an endocrinologist wishing to participate in a PTCOE 
needs to have received basic training in internal medicine 
and endocrinology though the residency stage, and then 
to perform postgraduate training for at least 12 months as 
part of a group of experts in pituitary disorders that has 
international stature.
The expert endocrinologist must have a through knowl-
edge of the laboratory techiques for hormone analy-
sis because diagnosis is based on the accurancy of such 
techiques. Analytical methods are complex and a true knowl-
edge of reagents, calibrators and degree of standarization is 
mandatory. An adequate understanding of modern genetic 
techiques is also relevant for diagnosis. An expert endocri-
nologist must be able to rudimentary understanding of MRI 
studies to being able to read/interpret and review pituitary 
MRI studies, understand pituitary pathology, significance of 
positive immunostaining in absence of clinical signs- such 
as silent corticotroph tumors, and the importance (and limi-
tations) of proliferative indices in regard to tumor growth.
To substantiate excellence, the endocrinologist should 
present results at scientific meetings and contribute to the 
advance of pituitary science. This can be supported by 
regular publications of peer-reviewed research articles, 
reviews, chapters in monographs or textbooks, participa-
tion in scientific or consensus meetings, as well as by regu-
lar participation in multi- center trials of novel pituitary-
directed treatments strategies (Fig. 1).
Box 7. Experience of the endocrinologist working at a PTCOE
1. Specialty medical training in internal medicine or adequate alter-
natives and in endocrinology
2. Postgraduate training at a center with a unit dedicated to pituitary 
disorders
3. Working at a PTCOE with intense activity and a high workload
4. Presenting results at scientific events and to health administration 
bodies
5. Contributions to the advancement of pituitary science, and dis-
covery in pituitary medicine
PTCOE
Leading
TEAM
ENDOCRINOLOGIST NEUROSURGEON
Supporting
UNITS
Neuroradiology
Neuropathology
Radiation Oncology
Neuro-ophthalmology
Fig. 1  General structure of a Pituitary Tumors Center of Excellence 
(PTCOE). The leading team composed by the endocrinology and by 
neurosurgery teams, and the main supportly units of other specialities
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Supporting units for a PTCOE
The close relationship of expert pituitary surgeons and 
pituitary endocrinologists requires the additional support 
of several specialties to provide a high-level standard of 
care. For imaging analysis, a group of well-trained neu-
roradiologists is ordinarily available in most centers and 
in all academic units. However in certain circumstances, 
familiarity with specific protocols to locate often small 
microadenomas in for example Cushing disease is of 
importance in a full PTCOE. For diagnosis, reports from 
the neuropathologist should include tumor immunocy-
tochemistry to make full diagnosis and comments if the 
tumor exhibits unusually high proliferative potential as 
this may have bearing on subsequent management. There 
may be the need for close surgical collaboration between 
neurosurgery and otolaryngology in the execution of 
endonasal and other skull-base approaches. Neuro-oph-
thalmologists are required for the diagnosis and, in some 
cases, for follow-up. The contribution of such specialties 
is mandatory to provide a given PTCOE its necessary sup-
port [9, 39–47].
BOX 8. Units providing support to a PTCOE
1. Neuroradiology
2. Neuropathology, including molecular diagnosis
3. Radiation neuroncology
4. Neurooncology
5. Neuro-ophthalmology
6. Specialized clinical and research nursing
Expert Neuroradiology Unit
At a minimum, high field magnetic resonance imaging 
(MRI) with at least 1.5 T field strength and high resolu-
tion depiction of the sellar region should be available for 
every patient with a pituitary tumor throughout the day. In 
addition, around the clock availability of thin-collimation 
computerized tomography is required for those who have 
contraindications to MRI. Orientation of the sections and 
labelling of the images should be standardized to enable 
reliable follow-up studies. The centre should have access 
to digital substraction angiograpy, and to expert selective 
bilateral venous sampling of the inferior petrosal sinus.
Expert Neuropathology Unit
Tumor Pathology is an essential aspect of the diagnosis, 
management and follow-up of patients with pituitary and 
related disorders. The pathologic diagnosis guides the opti-
mal therapeutic strategy, and helps to determine the response 
to treatment and the prognosis for the patient.
The ideal arrangement for Pathology to be an integral 
part of the multidisciplinary PTCOE would be as follows:
BOX 9. Neuropathology unit
1. One or two experienced neuropathologists or endocrine patholo-
gists who will have responsibility for the final diagnosis
2. Routine assessment of histology—mitoses, pleomorphism, giant 
cells, inclusions, inflammatory changes, stroma, hemorrhage, 
vascular features. Proliferative index Ki67. Routine stains
3. Routine pituitary hormone stains ACTH, prolactin, growth 
hormone, TSH, LH, FSH, and additionally in some cases alpha 
subunit, chromogranin, P53, hormone receptor stains, transcrip-
tion factors
4. Tumor specimen banking
5. A standard report indicating a final diagnosis using the most 
current WHO guidelines and criteria with commentary on normal 
pituitary gland incorporated in the specimens
Radiation Neuroncology Units of Excellence
Radiation therapy is required to treat some pituitary tumors 
that are completely or partially resistant to medical treat-
ment, or for surgical remnants from such tumors, patients 
who refuse or cannot undergosurgery,aggressive pituitary 
tumors or in pituitary cancers. In all of these cases, LINAC 
radiotherapy, stereotactic radiotherapy or radio-surgery, all 
of which are computer-assisted techniques performed by 
radiotherapists expert in the treatment of intracranial tumors, 
are necessary at a high level PTCOE [48–57].
Single fraction stererotactic radiosurgery (single dose) 
or fractionated stereotactic treatmentneed to be accessible 
from the center of excellence, to be utilized depending on 
patient and tumor related factors. Radiation neuroncologists 
treating patients with pituitary adenomas must have an in-
depth knowledge of the tolerance of the optic system, cranial 
nerves of the cavernous sinus, temporal lobes and the normal 
pituitary gland. They should also understand the temporal 
relationship between the delivery of radiation and the inter-
val for development of such complications as hypopituita-
rism. Radiation oncologists should work in close coopera-
tion with the neuroendocrinologists and neurosurgeons.This 
should also allow selected radiotherapists to gain enough 
experience in the treatment of pituitary tumors.
In some national Health Systems, radiation neurooncol-
ogy units are not located in every high level hospital but 
at specific centers. In such situations close relationship 
between radiotherapists and neuroendocrinologists must be 
guaranteed.
All of these different specialties working in a team with 
neurosurgeons and expert neuroendocrinologists form the 
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core of a PTCOE. The internal architecture of the unit and 
facilities should allow intense collaborative and interdisci-
plinary functioning. In some national Health Systems there 
are regional endocrine centers of high quality that may inter-
act with a PTCOE. A bidirectional flux the patients would 
guarantee the best care for patients suffering of pituitary 
pathologies (Fig. 2).
Conclusions
In the last few decades, a considerable body of evidence sup-
ports the concept that patients with pituitary tumors would 
receive the best care from units of excellence composed of 
expert neurosurgeons performing pituitary surgery by trans-
sphenoidal and other approaches, plus experienced neu-
roendocrinologists devoted to these types of tumors. These 
experts, working in liaison with supporting units, would 
form a center of excellence for pituitary tumors (PTCOE). 
Such a center would be the optimal organization for patients, 
the most cost-effective for health administrators, and a more 
suitable structure to allow for derivation and presentation of 
results, and advancement of pituitary science. The present 
document is intended to provide the basis for such a PTCOE 
structure.
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